

Microba Appoints CRO for IBD Clinical Trial

- Microba has appointed Beyond Drug Development to support upcoming clinical trial for MAP 315
- The MAP 315 lead candidate was identified using Microba's human first, data driven Therapeutic Platform with promising pre-clinical efficacy and safety
- Manufacturing and regulatory activities are on track to support the clinical study

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a commercial stage microbiome company, has appointed Beyond Drug Development as the lead Contract Research Organisation (CRO) for its upcoming Phase 1 trial of novel microbial cell therapy, MAP 315, for the treatment of Ulcerative Colitis, the most prevalent form of Inflammatory Bowel Disease (IBD).

The lead candidate for the MAP 315 program was discovered using Microba's human first, data driven Therapeutic Platform, and has demonstrated strong efficacy and an excellent safety profile in pre-clinical development.

Beyond Drug Development, based in Brisbane, Australia, is a CRO with a special focus on product development and early phase research. Beyond will bring extensive industry experience to the MAP 315 study, through its expert team (averaging 20 years' experience) and continuously growing reputation in serving biotech companies like Microba, as well as established pharmaceutical companies.

In addition to this partnership with Beyond Drug Development, Microba have selected Nucleus Network as the preferred clinical trial site. Located within cutting-edge health precincts, Nucleus Network provides accelerated clinical development solutions supported by advanced technology, clinical excellence and research expertise.

The MAP 315 Phase 1 study is scheduled for commencement in late 2022.

The study will be conducted as a Phase 1, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MAP 315 in Healthy Adults. This study will form the basis for rapidly transitioning into a Phase 2 efficacy study in Ulcerative Colitis patients.

cGMP manufacturing is on track with Microba's manufacturing partner Bacthera in Switzerland to deliver clinical doses of MAP 315 for the trial.

Prof. Trent Munro, SVP of Therapeutics at Microba, commented, "This is a significant step forward for Microba as we accelerate our MAP 315 program into clinical trials. We look forward to this partnership with Beyond Drug Development and Nucleus Network for this Phase 1 study."

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Simon Hinsley

Investor / Media Relations

E: simon@nwrcommunications.com.au

T: +61 401 809 653

Microba Life Sciences Ltd ABN 82 617 096 652

Level 10, 324 Queen Street, Brisbane QLD 4000 Australia

T: 1300 974 621 E: investor@microba.com W: microba.com

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.